05

2025y02m

Belief BioMed Announces IND Acceptance by NMPA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, February 5th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) acceptance of an Inves…

25

2025y01m

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, January 22th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an Investigationa…

06

2024y11m

Belief BioMed's Gene Therapy for DMD Receives Orphan Drug Designation & Rare Pediatric Disease Designation from the U.S. FDA

Shanghai, China, November 06, 2024 — Belief BioMed Inc. (hereinafter, "BBM"), a globally innovative biotech company focusing on cutting-edge gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Or

25

2024y10m

Great news! The gene therapy for hemophilia B developed by Belief BioMed has received Advanced Therapy Medicinal Product Designation from the EMA!

Shanghai, China, September 25, 2024 — Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announced a new strategic collaboration with Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and

25

2024y09m

Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

Shanghai, China, September 25, 2024 — Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announced a new strategic collaboration with Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and

24

2024y07m

Belief BioMed’s New Drug Application for BBM-H901, a gene therapy product for hemophilia B, has been accepted by the National Medical Products Administration of China

Shanghai, China, July 24th, 2024 —— Belief BioMed (BBM), an innovative Chinese biotechnology company focused on developing cutting-edge gene therapies, announced today that the Medical Products Administration (NMPA) of China has accepted the company’s n…

03

2024y01m

Good News | Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

Shanghai, China, 3rd January, 2024—— Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a…

18

2023y10m

Belief BioMed and Takeda China Announced Exclusive Commercial Partnership in the Field of Hemophilia B，Bringing Innovative Gene Therapy to Chinese Patients

(Shanghai, China, October 17, 2023) – Belief BioMed Inc. announced today that it has signed an exclusive cooperation agreement with Takeda China. According to the agreement, Belief BioMed will grant Takeda China the exclusive license for the commercializa

23

2023y04m

Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901

Shanghai, China, 24th April, 2023 —— Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced today the completion of patient dosing in its Phase III Registrational Clinical Trial (CTR20212816) of BB…

22

2022y12m

Belief BioMed’s Second AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA

Belief BioMed (BBM, Company) announced today that its self-developed and manufactured BBM-H803 injection was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia A on December 21, 2022. It i